Business Context and Reporting Period
Company: iBio, Inc. (formerly iBioPharma, Inc.)
Filing Type: Form 10-Q (Unaudited)
Period Ended: December 31, 2009
Business Overview: iBio is a biotechnology company focused on developing vaccines and therapeutic proteins using proprietary plant-based technology. The company discontinued its nutritional supplement business effective April 1, 2009, transferring those assets to a former parent subsidiary in exchange for a 5% royalty. Current focus is on advancing H1N1 and H5N1 influenza vaccine candidates to clinical trials.
Key Financial Metrics
| Metric | Three Months Ended Dec 31, 2009 | Six Months Ended Dec 31, 2009 |
|---|---|---|
| Revenue (Sales) | $0 | $0 |
| Net Loss | $(306,671) | $(1,851,033) |
| Operating Loss | $(756,955) | $(1,329,374) |
| Cash and Cash Equivalents | $3,001,016 | $3,001,016 |
| Working Capital | $1,354,554 | $1,354,554 |
| Total Liabilities | $2,705,823 | $2,705,823 |
| Derivative Liability | $740,819 | $740,819 |
Cash Flow (Six Months): Net cash used in operating activities was $(487,303). Net cash used in investing activities was $(348,399). Net cash provided by financing activities was $2,797,474, primarily from the sale of common stock and warrants.
Material Changes vs. Prior Period
- Revenue Elimination: Sales dropped to zero from $379,132 (three months) and $712,560 (six months) in the prior year due to the discontinuance of the nutritional supplement business in April 2009.
- Derivative Instrument Impact: The adoption of ASC 815-40 resulted in significant non-cash fluctuations. For the three months ended Dec 31, 2009, a $441,141 non-cash gain was recorded due to a decrease in the fair value of derivative liabilities. For the six-month period, a $541,430 non-cash expense was recorded.
- Operating Expenses: Research and development expenses decreased by 20% (three months) and 43% (six months) compared to the prior year, largely due to personnel cost reductions as staff moved to a partner entity (FhCMB). General and administrative expenses increased due to financial advisory and investor relations fees associated with operating as a standalone public entity.
- Liquidity: Cash increased by approximately 189% from $1.04 million (June 30, 2009) to $3.00 million (Dec 31, 2009) following a September 2009 equity financing.
Guidance, Outlook, and Risks
Outlook and Liquidity: Management expects current cash and working capital resources to support operations through the summer of 2010. The company plans to fund future activities through licensing arrangements or additional equity sales. There is a significant commitment to pay $10 million to FhCMB for R&D services through May 2014, with a $1 million installment paid in January 2010.
Material Weakness in Internal Controls: The company's independent auditors identified a material weakness in internal control over financial reporting. This weakness involved deficiencies in accounting for non-routine, complex transactions, specifically the delayed implementation of ASC 815-40 regarding derivative instruments. This required the restatement of financial statements for the quarter ended September 30, 2009.
Risks: The company operates under a "going concern" assumption dependent on obtaining additional financing. Failure to raise funds could force the company to delay development, seek unfavorable collaborators, or relinquish technology rights. Additionally, the derivative liability is subject to significant volatility based on stock price fluctuations.
Investor Verification Checklist
- Derivative Liability Volatility: Verify the sensitivity of the $740,819 derivative liability to stock price changes, as this creates significant non-cash income/expense volatility.
- Capital Runway: Confirm the timeline for cash depletion (projected summer 2010) and the status of any new financing efforts.
- R&D Commitments: Review the $10 million commitment to FhCMB and the company's ability to meet future $1 million installments without additional funding.
- Internal Controls: Assess the progress of remediation efforts regarding the material weakness in financial reporting identified by auditors.
- Revenue Model: Understand the reliance on future licensing deals and royalties, given the complete absence of product sales revenue in the current period.